The Use of Continuous Glucose Monitoring in Patients with Type 2 Diabetes

Meade, Lisa T.

doi:10.1089/dia.2011.0086

Cited by 15 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This condition exposes pregnant women to a higher risk of fetal congenital malformations and overgrowth during the second and third trimesters [32], so monitoring with HBGI is strongly recommended. As mentioned previously, SMBG only detects a small proportion of these fluctuations [39]. …”

Section: Discussionmentioning

confidence: 98%

Glucose Fluctuations during Gestation: An Additional Tool for Monitoring Pregnancy Complicated by Diabetes

Dalfrà

Chilelli²,

Cianni³

et al. 2013

International Journal of Endocrinology

View full text Add to dashboard Cite

Continuous glucose monitoring (CGM) gives a unique insight into magnitude and duration of daily glucose fluctuations. Limited data are available on glucose variability (GV) in pregnancy. We aimed to assess GV in healthy pregnant women and cases of type 1 diabetes mellitus or gestational diabetes (GDM) and its possible association with HbA1c. CGM was performed in 50 pregnant women (20 type 1, 20 GDM, and 10 healthy controls) in all three trimesters of pregnancy. We calculated mean amplitude of glycemic excursions (MAGE), standard deviation (SD), interquartile range (IQR), and continuous overlapping net glycemic action (CONGA), as parameters of GV. The high blood glycemic index (HBGI) and low blood glycemic index (LBGI) were also measured as indicators of hyperhypoglycemic risk. Women with type 1 diabetes showed higher GV, with a 2-fold higher risk of hyperglycemic spikes during the day, than healthy pregnant women or GDM ones. GDM women had only slightly higher GV parameters than healthy controls. HbA1c did not correlate with GV indicators in type 1 diabetes or GDM pregnancies. We provided new evidence of the importance of certain GV indicators in pregnant women with GDM or type 1 diabetes and recommended the use of CGM specifically in these populations.

show abstract

Section: Discussionmentioning

confidence: 98%

Glucose Fluctuations during Gestation: An Additional Tool for Monitoring Pregnancy Complicated by Diabetes

Dalfrà

Chilelli²,

Cianni³

et al. 2013

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In the past decade, the CGMS have evolved from a research tool to a device useful for real‐time glucose monitoring in daily clinical practice in human medicine. CGMS improve glycemic control in diabetic patients and allow recognition of episodes of hypoglycemia, which are missed with the conventional fingerstick monitoring . In recent years, several studies addressed the use of CGMS in critical care settings .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a continuous glucose monitoring system compared with an in‐house standard laboratory assay and a handheld point‐of‐care glucometer in critically ill neonatal foals

Hug

Riond

Schwarzwald

2013

J Vet Emergen Crit Care

View full text Add to dashboard Cite

The CGMS may be helpful for monitoring a trend in interstitial glucose concentration in critically ill neonatal foals. However, considering the wide limits of agreement between methods, the CGMS should only be used as an adjunctive device to other, more accurate and readily available methods that are able to detect acute changes in glucose concentration. Its use is further limited by the relatively high costs of the sensors, the mandatory 2-hour initialization period, and the difficulties of keeping the transducer in place in an active foal. The POC glucometer used in this study is easy to use and proved to be sufficiently accurate for repeated, stall-sided glucose monitoring in neonatal foals.

show abstract

“…97,98 In contrast to patients with T1DM, insulin-resistant patients with T2DM require larger amounts of insulin per day. 99 For many insulin pumps, the maximal bolus dose is limited, which may preclude adequate bolus administrations for patients with T2DM. Moreover, due to the use of high doses of U-100 insulin, more frequent insulin reservoir changes are needed in such patients.…”

Section: Barriers and Solutions To Insulin Pump Use In T2dmmentioning

confidence: 99%

Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies

Freckmann

Buck

Waldenmaier

et al. 2020

J Diabetes Sci Technol

View full text Add to dashboard Cite

An increasing number of patients with type 2 diabetes mellitus (T2DM) use insulin pumps. The first insulin pumps especially designed for patients with T2DM have recently become available. However, national guidelines do not primarily recommend the use of continuous subcutaneous insulin infusion (CSII) for this patient group. The effectiveness of CSII in T2DM has not yet been convincingly demonstrated, despite some positive evidence. An overview and an assessment of various studies to date will be given. T2DM is a heterogeneous disease with a substantial phenotypic variability; therefore, it is difficult to provide general conclusions about the effectiveness of CSII in T2DM therapy. The pump types, characteristics, and associated barriers may play a relevant role for therapy outcome. Most advanced functions like various bolus dosages offered by conventional insulin pumps are not needed for T2DM treatment and complicate the device handling for this subject group. Additionally, new technologies like increased connectivity, advanced software features, and interoperability are currently becoming available representing further barriers. The implementation of this technological progress might be a benefit for pumps for T2DM as well. However, these have not been sufficiently examined either and increased security challenges due to integrated peripheral components should not be neglected in terms of a sound cybersecurity. Pump features and handling for patients with T2DM should be as easy as possible, indicating a need for insulin pumps specially designed for patients with T2DM. However, it has to be investigated if pumps designed for T2DM are more effective than other intensified insulin regimens.

show abstract

The Use of Continuous Glucose Monitoring in Patients with Type 2 Diabetes

Cited by 15 publications

References 26 publications

Glucose Fluctuations during Gestation: An Additional Tool for Monitoring Pregnancy Complicated by Diabetes

Glucose Fluctuations during Gestation: An Additional Tool for Monitoring Pregnancy Complicated by Diabetes

Evaluation of a continuous glucose monitoring system compared with an in‐house standard laboratory assay and a handheld point‐of‐care glucometer in critically ill neonatal foals

Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies

Contact Info

Product

Resources

About